Back to results
US RE38,628 E1Granted
Pharmaceutical compositions
AssigneeFisons Limited
InventorsAndrew R. Clark, Paul Wright, Julia H. Ratcliffe
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeFisons Limited
InventorsAndrew R. Clark, Paul Wright, Julia H. Ratcliffe
Estimating the term…
A method of treatment of a condition selected from the group comprising conjunctivitis, keratitis, ‘allergic eyes’, adenovirus infections, corneal homograft rejection, anterior uveitis, nasal polyps, vasomotor rhinitis, allergic manifestations of the nasopharynx, reversible obstructive airways disease, Crohn's disease, distal colitis and proctitis, which method comprises administration to a patient suffering from such a condition of a therapeutically effective amount of an aqueous solution containing, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof. Also described are novel pharmaceutical compositions suitable for use in such methods of treatment.
A method of treating a reversible obstructive airways disease comprising administering, by inhalation, to a patient suffering from, or susceptible to, such a condition the nebulized contents of an ampoule of carbon dioxide permeable plastics material filled with a unit dose of an aqueous pharmaceutical solution containing, as active ingredient, from 0.1 to 5% w/v of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof, the solution having a pH of 3.5 to 6.0.
A method of controlling the symptoms of conjunctivitis comprising administering to the eye of a patient having conjunctivitis an effective amount of nedocromil sodium in an ophthalmically acceptable formulation.
A method of treatment of a disease selected from the group consisting of conjunctivitis, keratitis, allergic eyes, and anterior uveitis, which method comprises administering to the eye an effective amount of an ophthalmically acceptable aqueous pharmaceutical solution containing the active ingredient 9-ethyl-6,-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2g)quinoline-2,8-dicarboxylic acid, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.